目的：观察和探讨呼吸训练联合舒利迭治疗慢性阻塞性肺疾病Ⅲ、Ⅳ级稳定期的临床效果，以期为提高慢性阻塞性肺疾病稳定期临床效果提供客观的理论依据。方法：选取2014年1月-2015年1月于笔者所在医院就诊的慢性阻塞性肺疾病Ⅲ、Ⅳ级患者68例作为研究观察对象，入选观察对象均处于疾病稳定期，应用随机数字表法将观察对象随机分为观察组35例和对照组33例。对照组患者单纯给予舒利迭药物治疗及常规辅助治疗，而观察组在此基础上加予呼吸训练有效干预，观察和对比两组患者临床疗效。结果：治疗后，观察组的 PaO2、PaCO2、VC 和 FEV1与治疗前比较，均有明显改善，差异均有统计学意义(P<0.05)，且观察组较对照组肺功能相关指标均有明显改善，差异均有统计学意义(P<0.05)。两组治疗后的 mMRC 与治疗前比较，均有显著下降，差异均有统计学意义(P<0.05)，且观察组下降幅度明显大于对照组，差异有统计学意义(P<0.05)。结论：呼吸训练联合舒利迭治疗慢性阻塞性肺疾病Ⅲ、Ⅳ级稳定期临床效果显著，能够有效提高患者的肺功能，值得临床加以推广。%Objective:To study the clinical effect of respiratory training combined with Seretide in the treatment of typeⅢandⅣof COPD at stable phase, provide the objective theory basis for the improvements of its clinical effects.Method:68 patients with type Ⅲ and Ⅳ of COPD at stable phase treated from January 2014 to January 2015 in our hospital were selected,they were randomly divided into observation group(35 cases) and control group(33 cases).The control group just adopted Seretide combined with conventional adjuvant therapy,on the basis,the observation group also adopted the respiratory training,the clinical effect of two groups were observed and compared.Result:After treatment,the observation group PaO2,PaCO2,VC and FEV1 compared with before the treatment,were significantly improved,the differences were statistically significant(P<0.05),and the lung function index of the observation group were significantly improved than those in control group,the differences were statistically significant(P<0.05).After treatment,the two groups of mMRC were significantly decreased compared with before treatment,the difference was statistically significant(P<0.05),and the decrease of the observation group was significantly greater than that of the control group,the difference was statistically significant(P<0.05).Conclusion:The respiratory training combined with Seretide has an obvious clinical effect in the treatment of type Ⅲ and Ⅳ of COPD at stable phase and can effectively improve the patient’s pulmonary function,it is worthy of clinical promotion.
展开▼
